I now have all the content needed for a comprehensive exam-level answer. Let me write it up.
TETANUS - Comprehensive Exam Answer
1. DEFINITION
Tetanus is a toxin-mediated, non-communicable, potentially fatal disease characterized by generalized rigidity and convulsive spasms of skeletal muscles, caused by tetanospasmin - a potent neurotoxin produced by Clostridium tetani at the site of injury.
- Mortality: ~8% in the US, 35-40% globally, approaching 50% in patients >70 years
- Notable feature: patient remains conscious (lucid) unless complications arise; fever is usually absent unless secondary infection occurs
2. ETIOLOGY - THE ORGANISM
| Feature | Detail |
|---|
| Organism | Clostridium tetani |
| Type | Gram-positive, anaerobic, motile, non-encapsulated, slender bacillus |
| Spore shape | Drumstick / tennis racket shape (terminal, round spores) |
| Survival | Spores survive in soil and environmental surfaces for years |
| Natural habitat | Soil, animal (and human) feces - up to 10% of humans harbor it in the colon |
| Thrives in | Warm, damp climates; highly cultivated rural areas |
Two exotoxins produced:
- Tetanolysin - hemolysin; facilitates growth of bacterial population by destroying surrounding tissue
- Tetanospasmin - the neurotoxin responsible for ALL clinical manifestations; one of the most potent biological toxins known (lethal dose in humans: 2.5 ng/kg)
3. PATHOGENESIS & MECHANISM OF ACTION
Step-by-Step Pathogenesis:
Step 1 - Entry:
C. tetani spores enter the body through a wound (puncture, laceration, abrasion, burn, drug injection site, umbilical stump in neonates). The wound provides anaerobic conditions (low oxygen tension due to devitalized/crushed tissue, foreign body, or infection).
Step 2 - Germination:
Spores germinate into vegetative toxin-producing form in the low-oxygen wound environment. Bacteria remain localized - they do NOT invade tissues.
Step 3 - Toxin Production and Spread:
Tetanospasmin is released locally. It spreads by two routes:
- Hematogenous spread to peripheral nerve terminals throughout the body
- Retrograde intra-axonal transport (at ~75-250 mm/day) within membrane-bound vesicles, traveling up motor neurons to the spinal cord and brainstem. It does NOT cross the blood-brain barrier directly - retrograde transport is the key route to CNS access.
Step 4 - Mechanism at CNS:
"Tetanospasmin prevents the release of inhibitory neurotransmitters glycine and GABA (γ-aminobutyric acid) from presynaptic nerve terminals of Renshaw cells and other inhibitory interneurons in the spinal cord."
- Tintinalli's Emergency Medicine
The light chain of tetanospasmin is a zinc-dependent protease that cleaves synaptobrevin (VAMP - vesicle-associated membrane protein), a component of the SNARE complex essential for vesicle fusion and neurotransmitter release.
Result:
- Loss of inhibitory control → uninhibited, sustained motor neuron firing
- Simultaneous contraction of agonist AND antagonist muscles → tetanic spasms
- Loss of inhibition at preganglionic sympathetic neurons → autonomic dysfunction (sympathetic overactivity, high catecholamine levels)
Key Point: Toxin binding to nerve terminals is irreversible. Recovery depends on the growth of new axon terminals - this is why the disease lasts 4-6 weeks.
4. RISK FACTORS / PORTALS OF ENTRY
- Puncture wounds, lacerations, abrasions (most common - ~70% of cases)
- Contaminated wounds with soil/manure
- Chronic skin ulcers, abscesses
- Burn wounds
- Otitis media (cephalic tetanus)
- Injection drug users (50% of US cases)
- Neonates - through unclean umbilical cord care
- Childbirth/abortion (obstetric tetanus)
- Dental procedures
- Patients with diabetes, immunosuppression
- Waning immunity (>65 year age group, lack of booster vaccination)
5. INCUBATION PERIOD
- Usually 3 to 21 days (mean: 7-8 days), ranging from 4 to 14 days
- Shorter incubation = worse prognosis (toxin reaches CNS faster, meaning the wound is closer to the spinal cord)
6. CLINICAL TYPES
A. Generalized Tetanus (Most Common - 80-90%)
The classical form. Cephalocaudal progression.
- Trismus (lockjaw) - initial complaint in ~75% of cases - spasm of masseter muscles; patient often presents to a dentist first
- Risus sardonicus - persistent spasm of facial muscles producing a fixed, grimacing smile (see image below)
- Dysphagia - pharyngeal spasm
- Neck rigidity - opisthoclonus progressing to full opisthotonus
- Opisthotonus - severe arching of the back due to paraspinous muscle spasm (extensor muscles dominate)
- Generalized convulsive spasms - precipitated by any stimulus (noise, light, touch)
- Respiratory failure - laryngeal spasm causing apnea; the most common cause of death
- Autonomic Nervous System Dysfunction (ANSD) - appears in week 2 of severe disease (see below)
Risus sardonicus in a tetanus patient (Bailey & Love's, 28th Ed.)
B. Localized Tetanus
- Muscle spasms confined to the area near the wound
- Can progress to generalized tetanus
- Mild form; persistent contractions in the affected extremity
- Relatively rare
C. Cephalic Tetanus
- Follows head injuries or middle ear infection (otitis media)
- Involves cranial nerves - most commonly facial nerve palsy
- Short incubation: 1-2 days
- Can involve laryngeal/pharyngeal muscles - aspiration, respiratory failure, airway obstruction
- Often progresses to generalized tetanus
D. Neonatal Tetanus (Tetanus Neonatorum)
- Occurs in neonates of unimmunized mothers through unclean umbilical cord practices
- Presents on days 3-10 of life
- Features: inability to suck, poor feeding, generalized spasms, irritability, opisthotonos
- WHO estimates ~34,000 neonatal deaths/year
- Differential: Hypocalcemia, meningoencephalitis, septicemia
7. ABLETT CLASSIFICATION OF SEVERITY
| Grade | Severity | Features |
|---|
| I | Mild | Mild trismus, general spasticity; NO respiratory compromise, NO spasms, NO dysphagia |
| II | Moderate | Moderate trismus, rigidity, SHORT spasms, mild dysphagia, moderate respiratory involvement (RR >30/min) |
| III | Severe | Severe trismus, generalized rigidity, PROLONGED spasms, severe dysphagia, apneic spells, pulse >120/min, RR >40/min |
| IV | Very Severe | Grade III + Autonomic Dysfunction |
8. AUTONOMIC NERVOUS SYSTEM DYSFUNCTION (ANSD)
- Occurs in week 2 of severe tetanus
- Death due to cardiovascular events becomes the leading risk at this stage
- Features:
- Labile BP - hypertension alternating with hypotension
- Labile heart rate - tachycardia alternating with bradycardia
- Profuse diaphoresis
- Hyperthermia
- Gastrointestinal stasis
- Increased tracheal secretions
- Rhabdomyolysis
- Urinary retention
- Cause: tetanospasmin blocks inhibitory input to preganglionic sympathetic neurons, leading to catecholamine surge
9. DIAGNOSIS
Tetanus is a CLINICAL DIAGNOSIS. There is no confirmatory lab test.
Diagnostic criteria (CDC): Acute onset of hypertonia and/or painful muscular contractions of jaw/neck + generalized muscle spasms without other apparent medical cause.
Laboratory findings:
- Wound culture: C. tetani can be isolated in only 30% of cases; a positive culture alone is NOT confirmatory
- Serum anti-tetanus IgG: levels >0.1 IU/mL are considered protective and argue against tetanus; levels below this support the diagnosis
- PCR / recombinase polymerase amplification for tetanus neurotoxin gene - promising but not routinely available
- Spatula test (tongue depressor test): touching the posterior pharynx with a spatula elicits reflex masseter spasm (positive in tetanus) rather than gag reflex - this bedside test has high sensitivity
Investigations to consider:
- ABG - for respiratory status
- Electrolytes, creatinine, LFTs - baseline
- CK - elevated (rhabdomyolysis)
- ECG - cardiac arrhythmias
- Wound swab culture
10. DIFFERENTIAL DIAGNOSIS
| Condition | Distinguishing Feature |
|---|
| Strychnine poisoning | History of ingestion; trismus is NOT prominent; facial muscle is spared |
| Dystonic reaction (antidopaminergic drugs - metoclopramide) | Responds promptly to anticholinergics; history of drug use |
| Neuroleptic Malignant Syndrome | Altered consciousness, hyperthermia, rigidity, elevated CK; antipsychotic use |
| Stiff Person Syndrome | Gradual onset; anti-GAD antibodies; responds to diazepam |
| Hypocalcemic tetany | Positive Chvostek/Trousseau signs; low serum calcium; carpal/pedal spasm, NOT trismus |
| Peritonitis | Abdominal rigidity but not generalized; fever; guarding/rebound; normal jaw |
| Meningoencephalitis | Altered consciousness; CSF changes; trismus not prominent |
| Rabies | Hydrophobia; encephalitic features; history of bite |
| Cephalic tetanus | Can mimic oropharyngeal infection, cranial nerve palsies, peritonsillar abscess |
11. MANAGEMENT
Management has four simultaneous goals:
- Neutralize circulating unbound toxin (antitoxin)
- Remove source of toxin production (wound care + antibiotics)
- Control spasms and support vital functions
- Manage autonomic dysfunction and complications
A. General Supportive Care
- Admit to ICU - quiet, darkened room (minimize sensory stimuli - noise and light trigger spasms)
- Secure airway early in Grade III/IV tetanus - early elective tracheostomy is preferred over orotracheal intubation (which itself can trigger spasm)
- Mechanical ventilation if needed (may require weeks)
- Nasogastric tube for feeding (due to dysphagia)
- DVT prophylaxis, bladder care, pressure sore prevention
- Nutritional support
B. Antitoxin (Passive Immunization)
- Neutralizes only circulating, unbound toxin - does NOT reverse already-bound toxin
- Give EARLY before wound debridement
| Preparation | Dose | Notes |
|---|
| Human Tetanus Immunoglobulin (HTIG) - DRUG OF CHOICE | 500 - 5000 IU IM (single dose) | Less risk of anaphylaxis; preferred wherever available |
| Equine antitoxin | 10,000-20,000 U IM after hypersensitivity testing | Used in low/middle-income countries; higher risk of serum sickness |
| Intrathecal HTIG | - | Recent RCT: showed no additional benefit over IM route |
C. Wound Care
- Identify and debride the wound - remove all necrotic tissue, foreign bodies, pus
- Perform wound care several hours AFTER antitoxin administration
- Failure to debride may cause recurrent/prolonged tetanus
D. Antibiotics
- Metronidazole - DRUG OF CHOICE: 400 mg rectally or 500 mg IV every 6 hours for 7 days
- Penicillin - Alternative (but AVOID if possible - it competitively inhibits GABA receptors, theoretically worsening spasms; one study showed increased mortality)
E. Control of Spasms
| Drug | Mechanism | Notes |
|---|
| Benzodiazepines (Diazepam, Midazolam) | GABA-A agonist - enhances inhibitory neurotransmission | First-line; patients can tolerate high doses; continuous midazolam preferred for prolonged use; high-dose diazepam can cause hyperosmolarity + lactic acidosis |
| Magnesium Sulfate | Blocks neuromuscular junction; inhibits catecholamine release | Used for both spasm control AND autonomic dysfunction; maintain plasma level 2-4 mmol/L |
| Neuromuscular Blocking Agents (vecuronium, pancuronium) | Non-depolarizing NMBDs | When sedatives alone cannot control spasms; requires mechanical ventilation |
| Baclofen (intrathecal) | GABA-B agonist | Alternative in refractory cases |
| Propofol infusion | Sedation | Alternative for sedation; caution with prolonged use (propofol infusion syndrome) |
F. Management of Autonomic Dysfunction
- Magnesium sulfate - first-line (controls both hypertension AND tachycardia; plasma level 2-4 mmol/L)
- Beta-blockers (labetalol, propranolol, esmolol) - for persistent tachycardia/hypertension (use cautiously - can cause sudden cardiac arrest due to loss of sympathetic compensation)
- Calcium channel blockers - alternative
- Vasopressors (norepinephrine) - when parasympathetic predominance causes hypotension and bradycardia
G. Immunization (Active)
- Since tetanospasmin is poorly immunogenic, surviving tetanus does NOT confer immunity
- All patients must receive a full primary immunization course during or after recovery
12. VACCINATION SCHEDULE (WHO / CDC Recommendations)
| Schedule | Details |
|---|
| Primary series (infants) | 3 doses of DTP at 6 weeks, 10 weeks, 14 weeks (WHO) / 2, 4, 6 months (CDC); 4-week minimum interval |
| 1st Booster | 12-23 months |
| 2nd Booster | 4-7 years |
| 3rd Booster | 9-15 years |
| Adult booster | Every 10 years (Td/Tdap) |
| Wound prophylaxis | Booster if >5-10 years since last dose; HTIG if unvaccinated/unknown status |
Wound Management Algorithm:
| Wound Type | Vaccination Status | Action |
|---|
| Clean, minor wound | Up to date | Toxoid only if >10 years since last dose |
| Clean, minor wound | Unknown/incomplete | Toxoid |
| Tetanus-prone wound | Up to date | Toxoid if >5 years since last dose |
| Tetanus-prone wound | Unknown/incomplete | Toxoid + HTIG (250 IU IM, different sites) |
13. COMPLICATIONS
- Respiratory failure / Aspiration pneumonia - most common cause of death
- Cardiovascular events - autonomic dysfunction (Week 2 peak risk)
- Rhabdomyolysis - from sustained muscle contractions
- Vertebral / long bone fractures from violent spasms
- Pulmonary embolism
- Hospital-acquired infections (VAP, bloodstream infections, UTI) - due to prolonged ICU stay
- Pressure sores, muscle weakness - from immobility and high-dose sedation
- Laryngeal spasm leading to asphyxia - most immediate life-threatening event
- Neonatal sequelae: neurological - cerebral palsy, deafness, learning disabilities
14. PROGNOSIS
- Recovery usually takes 4-6 weeks (time for new axon terminals to grow)
- Shorter incubation period → worse prognosis
- Shorter period of onset (time from first symptom to first generalized spasm) → worse prognosis
- Scoring systems:
- Tetanus Severity Score (TSS) - most accurate (sensitivity 66%, specificity 91%)
- Dakar Score (6 parameters: incubation period, period of onset, portal of entry, spasms, fever, tachycardia)
- Phillips Score
15. HIGH-YIELD EXAM POINTS - QUICK SUMMARY
| Point | Answer |
|---|
| Organism | Clostridium tetani - spore-forming, anaerobic, Gram-positive |
| Spore shape | Drumstick/tennis racket |
| Neurotoxin | Tetanospasmin (light chain = zinc protease; cleaves synaptobrevin/VAMP) |
| Mechanism | Blocks release of Glycine + GABA from inhibitory interneurons |
| Most common clinical type | Generalized tetanus (80-90%) |
| First symptom | Trismus (lockjaw) - in 75% of cases |
| Facial sign | Risus sardonicus |
| Back posture sign | Opisthotonus |
| Stimulus sensitivity | Spasms triggered by noise, light, touch |
| Most common cause of death | Laryngeal spasm → respiratory failure |
| Week 2 danger | Autonomic dysfunction → cardiovascular death |
| Consciousness | Preserved (patient is lucid) |
| Diagnosis | Clinical - no confirmatory lab test |
| Spatula test | Reflex biting of spatula = positive (not gag reflex) |
| Antitoxin choice | HTIG 500-5000 IU IM |
| Antibiotic choice | Metronidazole 500 mg IV q6h (avoid penicillin) |
| Antispasmodic 1st line | Benzodiazepines (diazepam/midazolam) |
| Autonomic control | Magnesium sulfate (2-4 mmol/L) |
| Post-recovery immunity | None - must actively vaccinate |
| Booster interval | Every 10 years |
| Neonatal tetanus sign | Inability to suck, day 3-10 of life |
Sources: Harrison's Principles of Internal Medicine 22E (2025) | Tintinalli's Emergency Medicine | Goldman-Cecil Medicine | Bailey & Love's Short Practice of Surgery 28E